High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ira J DunkelJ L Finlay

Abstract

Medulloblastoma is a highly lethal disease when it recurs. Very few patients survive with conventional treatment. This study evaluated the use of high-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue (ASCR) in patients with recurrent medulloblastoma. Chemotherapy consisted of carboplatin 500 mg/m2 (or area under the curve = 7 mg/mL x min via Calvert formula) on days -8, -7, and -6; and thiotepa 300 mg/m2 and etoposide 250 mg/m2 on days -5, -4, and -3; followed by ASCR on day 0. In addition to the study-prescribed therapy, 21 patients received other treatment: neurosurgical resection in seven, conventional chemotherapy in 17, and external-beam irradiation in 11 cases. Twenty-three patients with recurrent medulloblastoma, aged two to 44 years (median, 13 years) at ASCR, were treated. Three patients died of treatment-related toxicities within 21 days of ASCR; multiorgan system failure in two, and Aspergillus infection with venoocclusive disease in one. Seven of 23 patients (30%) are event-free survivors at a median of 54 months post-ASCR (range, 24 to 78 months). Kaplan-Meier estimates of event-free (EFS) and overall survival are 34% +/- 10% and 46% +/- 11%, respectively, at 36 months post-ASCR. This stra...Continue Reading

Citations

May 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shakeel ModakJonathan L Finlay
Dec 3, 2004·Neurosurgery·Sridharan GururanganR Edward Coleman
Aug 22, 2006·Neurosurgical Focus·D R GoldB H Cohen
Oct 14, 2008·Pediatric Hematology and Oncology·Shih-Hsiang ChenTai-Ngar Lui
Mar 20, 2010·CNS Drugs·Laura J Klesse, Daniel C Bowers
Nov 26, 2010·Pediatric Blood & Cancer·Jane E MinturnJean B Belasco
Jul 8, 2011·The Cochrane Database of Systematic Reviews·Renée L MulderLeontien Cm Kremer
Dec 17, 2014·Pediatric Blood & Cancer·Robert J YoungIra J Dunkel
May 31, 2017·Cancer Control : Journal of the Moffitt Cancer Center·Sajeel ChowdharyMarc C Chamberlain
Apr 16, 2019·The Cochrane Database of Systematic Reviews·Renée L MulderElvira C van Dalen
Feb 24, 2001·Journal of Pediatric Hematology/oncology·A NarendranJ F Kelleher
May 6, 2004·Pediatric Transplantation·Sharon L Gardner
Feb 15, 2007·British Journal of Cancer·G J VealUNKNOWN UKCCSG Pharmacology Working Group
Mar 31, 2011·Onkologie·Katja SockelFrank Kroschinsky
Aug 25, 2009·Journal of Neuro-oncology·M Kashif IshaqiEric Bouffet
Sep 4, 2015·Journal of Child Neurology·Nathan E Millard, Kevin C De Braganca
Jun 28, 2015·Journal of Neuro-oncology·Richard E PhillipsYasmin Khakoo
Jun 27, 2019·Current Treatment Options in Oncology·Nazanin Majd, Marta Penas-Prado

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
B R MeisenbergL D Piro
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Sridharan GururanganPaul L Martin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
K K FieldsP E Zorsky
© 2021 Meta ULC. All rights reserved